34 crore people got jobs since 2014 in MSMEs: Manjhi in Rajya Sabha
The Minister of Micro, Small and Medium Enterprises gave the information while responding to supplementaries.
He said there is no dearth of money, and small workers are getting financial assistance under various schemes.
For Instance, he said, under the PM Vishwakarma Yojna, people such as cobblers and salon workers have received money.
Manjhi also spoke on promoting digital upgrade and adopting artificial intelligence in MSMEs in Haryana to enhance productivity and competitiveness.
'IndiaAI mission has been divided into seven pillars, such as IndiaAI Compute Capacity, IndiaAI Innovation Center, IndiaAI Application Development Initiative, IndiaAI Startup Financing, IndiaAI FutureSkills, IndiaAI Dataset Platform, and Safe & Trusted AI.
'We have been working under these pillars for the development of technology in Haryana," Manjhi said. PTI JP VN VN
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
20 minutes ago
- News18
Biocon Biologics launches product for autoimmune diseases in Australia
Agency: PTI Last Updated: New Delhi, Jul 23 (PTI) Biocon on Wednesday said its subsidiary Biocon Biologics has launched a product for the treatment of autoimmune diseases like rheumatoid arthritis, in the Australian market. The company has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia, the company said in a regulatory filing. Nepexto will be promoted by Generic Health, a local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in that country, it added. Etanercept is a fusion-protein that inhibits tumour necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Since receiving EU marketing authorisation in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen its immunology offering, it said. Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
20 minutes ago
- News18
Dixon Tech Shares Rise 3% After Robust Q1 Results: Buy, Sell Or Hold?
Shares of Dixon Technologies rose as much as 3% to Rs 16,540 on July 23 after the company posted a strong set of numbers for the Q1 Dixon Technologies Share Price: Shares of Dixon Technologies rose as much as 3% to Rs 16,540 on July 23 after the company posted a strong set of numbers for the first quarter of FY26. The electronics manufacturing services (EMS) major reported a 68% year-on-year (YoY) increase in net profit to Rs 225 crore, compared to Rs 134 crore in the same period last year. Revenue from operations surged 95% YoY to Rs 12,836 crore, while EBITDA grew 89% to Rs 484 crore. The EBITDA margin for the quarter stood at 3.8%. The mobile and other EMS segment remained a standout, with revenues climbing 125% YoY to Rs 11,663 crore. Segmental operating profit jumped 131% to Rs 395 crore, reinforcing the company's momentum in high-growth verticals. The results prompted mixed reactions from brokerages. Nomura maintained a 'Buy' rating on Dixon Technologies, assigning a target price of Rs 21,154, which implies a 31% upside from the last close. It noted that execution remains solid across mobile and component segments, and the Q1 earnings beat its estimates. Nomura expects the mobile production ramp-up to continue, with margin tailwinds likely from joint ventures. The brokerage sees EBITDA margins rising from 3.9% in FY26 to 4.4–4.7% in FY27–28. However, Morgan Stanley took a cautious stance, retaining an 'Underweight' rating with a target of Rs 11,563. It flagged a broad-based miss in revenues across most segments, and noted that while operating expenses and employee costs improved, EBITDA came in below its estimates and PAT was 11% short of expectations. The brokerage pointed to mixed margins across divisions and advised caution. Despite the earnings-driven rally, shares of Dixon Technologies are still down around 8% so far in 2025. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
35 minutes ago
- News18
ADB lowers India's FY26 growth forecast to 6.5 pc on trade, tariff concerns
Last Updated: New Delhi, Jul 23 (PTI) The Asian Development Bank (ADB) on Wednesday lowered India's growth forecast for FY26 to 6.5 per cent from 6.7 per cent on account of trade uncertainty and higher US tariffs that are expected to impact exports and investment. Despite the downward revision from the April 2025 Asian Development Outlook (ADO), India remains one of the fastest-growing major economies in the world. 'This revision is primarily due to the impact of US baseline tariffs and associated policy uncertainty. In addition to the effects of lower global growth and the direct impact of additional US tariffs on Indian exports, heightened policy uncertainty may affect investment flows," the July ADO said. Despite this, economic activity remains robust, with domestic consumption set to grow strongly on the back of revival of rural demand, it said. Services and agriculture sectors are expected to be key drivers of growth, the latter supported by a forecast of above-normal monsoon rains, it added. The Economic Survey has projected the GDP growth for FY26 between 6.3 per cent and 6.8 per cent, while RBI lowered its growth forecast from an earlier level of 6.7 per cent to 6.5 per cent for the ongoing financial year. India's economy grew by 6.5 per cent in the FY25, marking its slowest pace in four years. This growth was the slowest in four years and compared to a 9.2 per cent expansion in the previous 2023-24 fiscal. According to the report, the central government's fiscal position remains strong, with higher-than-expected dividends from the Reserve Bank of India, and it is on track to meet the targeted reduction in its fiscal deficit. In FY27, growth is projected to improve to 6.7 per cent on account of rising investments, under the assumption of reduced policy uncertainty and favourable financial conditions, backed by recent reductions in the repo rate and the cash reserve ratio by the monetary authorities, the report said. With inflation on a downward trend, the RBI's Monetary Policy Committee (MPC) has been reducing the benchmark repo rate and has adopted a neutral stance, which also gives the flexibility to either cut or hike the rate going forward. The central bank has cumulatively reduced the repo rate by 100 basis points since February this year. Last month, The RBI cut interest rates by more than expected 50 basis points, a third consecutive reduction, and unexpectedly reduced the cash reserve ratio for banks to provide a major liquidity fillip to support the economy amid geopolitical and tariff headwinds. It also cut the cash reserve ratio by 100 basis points to 3 per cent, adding Rs 2.5 lakh crore to already surplus liquidity in the banking system. The baseline expectations of lower crude oil prices will also support economic activity in FY26 and FY27, it added. PTI DP DR DR view comments First Published: July 23, 2025, 12:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
